Dr Owen O'Connor speaks to ecancer at ASH 2018 about the ECHELON-2 trial.
The ECHELON-2 trail tests brentuximab vedotin and CHP (A CHP) vs CHOP in the frontline treatment of patients with CD30 peripheral T-cell lymphomas.
Dr O'Connor describes the ways this large study was designed and run, and also details the results so far.
Watch his interview about the ACT-1 trial here.